4.6 Article

Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A

Journal

CELLS
Volume 11, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/cells11010136

Keywords

cystic fibrosis; drug discovery; F508del-CFTR; genetic revertants; intestinal organoids; low temperature; protein trafficking; rare mutations

Categories

Funding

  1. FCT Portugal [UIDB/04046/2020, UIDP/040467/2020, PD/BD/142857/2018]
  2. Gilead Sciences USA
  3. CFF USA [LOPES21I0, FARINHA19I0]
  4. FCT/MCTES Portugal [ERARE15-pp-010/JTC 2015]
  5. Fundação para a Ciência e a Tecnologia [PD/BD/142857/2018] Funding Source: FCT

Ask authors/readers for more resources

The study investigated the effects and mechanism of action of a newly developed F508del-CFTR corrector, MCG1516A, and found that it has additive effects to the FDA-approved corrector VX-661 in rescuing F508del-CFTR. Additionally, MCG1516A showed additive effects to genetic revertant R1070W, suggesting a potential binding site for this compound. This suggests that a combination of MCG1516A with other compounds could enhance correction of F508del-CFTR defects.
Although some therapeutic progress has been achieved in developing small molecules that correct F508del-CFTR defects, the mechanism of action (MoA) of these compounds remain poorly elucidated. Here, we investigated the effects and MoA of MCG1516A, a newly developed F508del-CFTR corrector. MCG1516A effects on wild-type (WT) and F508del-CFTR were assessed by immunofluorescence microscopy, and biochemical and functional assays both in cell lines and in intestinal organoids. To shed light on the MoA of MCG1516A, we evaluated its additivity to the FDA-approved corrector VX-661, low temperature, genetic revertants of F508del-CFTR (G550E, R1070W, and 4RK), and the traffic-null variant DD/AA. Finally, we explored the ability of MCG1516A to rescue trafficking and function of other CF-causing mutations. We found that MCG1516A rescues F508del-CFTR with additive effects to VX-661. A similar behavior was observed for WT-CFTR. Under low temperature incubation, F508del-CFTR demonstrated an additivity in processing and function with VX-661, but not with MCG1516A. In contrast, both compounds promoted additional effects to low temperature to WT-CFTR. MCG1516A demonstrated additivity to genetic revertant R1070W, while VX-661 was additive to G550E and 4RK. Nevertheless, none of these compounds rescued DD/AA trafficking. Both MCG1516A and VX-661 rescued CFTR processing of L206W- and R334W-CFTR with greater effects when these compounds were combined. In summary, the absence of additivity of MCG1516A to genetic revertant G550E suggests a putative binding site for this compound on NBD1:NBD2 interface. Therefore, a combination of MCG1516A with compounds able to rescue DD/AA traffic, or mimicking the actions of revertant R1070W (e.g., VX-661), could enhance correction of F508del-CFTR defects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available